PPAR-Gamma agonist rosiglitazone is neuroprotective after stroke in type II diabetic rodents

被引：0
|
作者：
Vemuganti, R. [1 ]
Tureyen, K. [1 ]
Satriotomo, I. [1 ]
Bowen, K. [1 ]
Kapadia, R. [1 ]
Feinstein, D. [2 ]
机构：
[1] Univ Wisconsin, Madison, WI USA
[2] Univ Illinois, Dept Anesthesiol, Chicago, IL USA
来源：
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM | 2009年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S253 / S253
页数：1
相关论文
共 50 条
  • [21] A PPAR-Gamma Agonist Rosiglitazone Suppresses Fibrotic Response in Human Pterygium Fibroblasts by Modulating the p38 MAPK Pathway
    Nuwormegbe, Selikem Abla
    Sohn, Joon Hyung
    Kim, Sun Woong
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (12) : 5217 - 5226
  • [22] PPAR-gamma agonist, ciglitazone, increases pigmentation and migration of human melanocytes
    Lee, Joong Sun
    Choi, You Mi
    Kang, Hee Young
    EXPERIMENTAL DERMATOLOGY, 2007, 16 (02) : 118 - 123
  • [23] Targeting inflammation by PPAR-gamma agonist in LPS induced pulmonary dysfunction
    Sharma, R.
    Kaundal, R. K.
    Kumar, A.
    Sharma, S. S.
    INDIAN JOURNAL OF PHARMACOLOGY, 2008, 40 : 151 - 151
  • [24] Development of a PPAR-gamma agonist-coated implant for restenosis treatment
    Haase, D.
    Wyrwa, R.
    Schnabelrauch, M.
    Otto, S.
    Poerner, T. C.
    EUROPEAN HEART JOURNAL, 2016, 37 : 640 - 640
  • [25] Process development of PPAR-gamma dominant agonist LY519818.
    Rizzo, JR
    Zhang, TY
    Wendel, SR
    Jones, CD
    Towsley, RW
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 226 : U192 - U192
  • [26] Effects of PPAR-gamma ligand rosiglitazone on liver fibrosis in chronic hepatitis C patients
    Passariello, N.
    Peluso, A.
    Passariello, G.
    Moniello, G.
    Maio, A.
    Mazo, S.
    Boccia, G.
    Esposito, A.
    JOURNAL OF HEPATOLOGY, 2007, 46 : S237 - S237
  • [27] Role of PPAR-gamma ligand rosiglitazone on the development of carrageenan-induced lung injury
    Cuzzocrea, S
    Dugo, L
    Di Paola, R
    Serraino, I
    Genovese, T
    Caputi, AP
    Thiemermann, C
    BRITISH JOURNAL OF PHARMACOLOGY, 2003, 138 : U20 - U20
  • [28] Effects of Angiotensin II Receptor Blocker (ARB) and PPAR-gamma Agonist on Vascular Failure in Patients with Hypertension, Diabetic Mellitus and Chronic Kidney Disease
    Watanabe, Hideki
    Nakagawa, Kunio
    Kakihana, Masaaki
    CIRCULATION, 2008, 118 (18) : S299 - S299
  • [29] Changes in brain white matter integrity after Ppar-gamma agonist treatment for cocaine use disorder
    Lane, Scott D.
    Hasan, Khader M.
    Mwangi, Benson
    Narayana, P. A.
    Vincent, Jessica
    Moeller, F. Gerard
    Steinberg, Joel
    Dineley, Kelly
    Cunningham, Kathryn A.
    Schmitz, Joy
    DRUG AND ALCOHOL DEPENDENCE, 2017, 171 : E113 - E114
  • [30] Glitazones, the anti-diabetic PPAR-gamma agonists, pose a significant risk of bone loss; Differential effects of rosiglitazone and netoglitazone
    Lecka-Czernik, B
    Suva, LJ
    Gaddy, D
    Rzonca, SO
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S24 - S24
12345